Role of chronic continuous intravenous lidocaine in the clinical management of patients with malignant type 3 long QT syndrome

Type 3 long QT syndrome (LQT3) is caused by pathogenic, gain-of-function variants in SCN5A leading to a prolonged action potential, ventricular ectopy, and torsades de pointes. Treatment options include pharmacotherapy, cardiac denervation, and/or device therapy. Rarely, patients with malignant LQT3 require cardiac transplantation.The purpose of this study was to evaluate the role of chronic continuous intravenous (IV) lidocaine as a therapeutic...